R&D Strategy and Organization
Through the inquisitive spirit of our researchers, alongside our desire to contribute to the betterment of humanity, we’re working to create a competitive pipeline and quickly and consistently deliver innovative products. This supports our vision of becoming a Global Pharma Innovator with Competitive Advantage in Oncology.
Research and development stage priority areas
By implementing research and development initiatives that precisely address unmet medical needs our Group is contributing to improve the rate of satisfaction towards medical care in future. Defining oncology as a primary focus area, we also aim to create advanced new drugs that revolutionize the SOC by advancing research and development targeting pain management, central nervous system disease, heart and kidney disease, and rare diseases as new horizon areas.
At the late-stage of development, in addition to oncology and cardiovascular-metabolics we are developing approaches to provide new treatment options for pain management.
Finally, in the life cycle management phase, we aim to provide continued medical benefits focused on our areas of strength, such as pain management, hypertension and thrombotic disorders.
Global decision-making and effective resource investment
The Daiichi Sankyo Group actively conducts discussions with scientific and business viewpoints in mind from the research stage, and endeavors to achieve more effective investment of manpower and material resources from a global perspective. Furthermore, we are constantly improving the meeting process and achieving swift decision-making while actively delegating authority. In particular, the Global Executive Meeting of Research And Development (GEMRAD), which makes “go/no-go” decisions on late-stage development projects, and Translational Research-GEMRAD (TR-GEMRAD), which handles early-stage development projects, have been established. As top decision-making bodies, they manage global R&D activities across functions and regions. Their members represent various divisions, including those responsible for R&D, pharmaceutical technology, product portfolios, licensing, pharmacovigilance, and finance, enabling both bodies to make appropriate decisions based on comprehensive assessments covering everything from research to marketing.
Moreover, global Integrated Project Teams (IPTs) and Translational Research Project Teams (TR-PTs) work under GEMRAD and TR-GEMRAD in a simple structure to propose project strategies and implement project plans, enabling fast and high quality project activities.
Regular priority evaluation is also conducted for early-stage development projects in progress, enabling effective resource investment based on portfolio strategy.
As of July 2016
Innovation born from diversity
Daiichi Sankyo Group research is carried out globally via a closely integrated network incorporating Japan, the United States, Germany. In Japan, alongside the nucleus of Daiichi Sankyo, there is Daiichi Sankyo RD Novare, which is responsible for technology platforms for drug development, and Asubio Pharma, which specializes in drug development research. Overseas, there is Plexxikon, which utilizes small molecule scaffold-based drug discovery, Daiichi Sankyo Life Science Research Centre in India (RCI), which focuses on creating drugs for inflammatory and infectious diseases, and the Tissue and Cell Research Center Munich (TCRM), which utilizes tissue research technology. Each advances new drug research by utilizing their respective strengths. Also, the Venture Science Research Laboratories based in Shinagawa, Tokyo, carries out innovative drug development research to find treatment for diseases with high unmet medical needs.
Our Group is unified across borders from Japan, the United States, and Europe, as well as bases across Asia, including India, South Korea and China, to advance global development by delivering drugs to more people around the world.
* An unincorporated division of Daiichi Sankyo, Inc.
Acceleration of Oncology R&D
While the medical needs of cancer are far from being fully addressed and new cancer cases are expected to rise from 14 million to 22 million over the next two decades. Moreover, as cancer rates increase with age, the ongoing aging of our society demands the rapid and timely delivery of innovative new cancer treatments to patients.
Defining oncology as a primary focus area in research and development, the Daiichi Sankyo Group has established a new global oncology research and development subunit unifying our research functions, including low-molecular-weight drugs and cancer biology and immunology, from research to development. Working together as a single expert team with high quality science and unified strategies, we continue to accelerate oncology R&D by rapid decision making. We make our best efforts to execute the delivery of new cancer treatments to patients as quickly as possible.
In order to quickly and consistently create competitive pipelines and innovative drugs, it is necessary to gather knowledge from both within and outside the company. The Daiichi Sankyo Group is actively advancing open innovation, and the TaNeDS Europe Programme, established in 2011, is one part of this. The program is continuing to achieve research results through collaboration, and the TaNeDS Global Program, which includes all EU member countries plus Norway and Switzerland, is having similar success.
In November 2013, a three-way research partnership was formed with two US companies Virtici and Celdara Medical, utilizing their academic connections to advance new drug discovery initiatives.
Even more recently, in April 2014, an agreement was signed with Astellas Pharma to enable the mutual exchange and use of each other’s chemical compound libraries, totaling around 400,000 compounds, for three years.
Through such initiatives maximizing efficient use of resources and knowledge, we hope to continue to achieve innovative drug creation.